- Home
- SANA vs COLL Comparison
SANA vs COLL Comparison
Compare SANA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- COLL
- Stock Information
- Founded
- SANA 2018
- COLL 2002
- Country
- SANA United States
- COLL United States
- Employees
- SANA N/A
- COLL N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SANA Health Care
- COLL Health Care
- Exchange
- SANA Nasdaq
- COLL Nasdaq
- Market Cap
- SANA 983.4M
- COLL 958.8M
- IPO Year
- SANA 2021
- COLL 2015
- Fundamental
- Price
- SANA $3.91
- COLL $30.07
- Analyst Decision
- SANA Strong Buy
- COLL Strong Buy
- Analyst Count
- SANA 6
- COLL 4
- Target Price
- SANA $10.00
- COLL $43.75
- AVG Volume (30 Days)
- SANA 5.5M
- COLL 284.4K
- Earning Date
- SANA 08-11-2025
- COLL 08-07-2025
- Dividend Yield
- SANA N/A
- COLL N/A
- EPS Growth
- SANA N/A
- COLL N/A
- EPS
- SANA N/A
- COLL 1.25
- Revenue
- SANA N/A
- COLL $664,283,000.00
- Revenue This Year
- SANA N/A
- COLL $20.23
- Revenue Next Year
- SANA N/A
- COLL $3.82
- P/E Ratio
- SANA N/A
- COLL $23.80
- Revenue Growth
- SANA N/A
- COLL 17.17
- 52 Week Low
- SANA $1.26
- COLL $23.23
- 52 Week High
- SANA $7.30
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SANA 47.52
- COLL 42.12
- Support Level
- SANA $4.72
- COLL $30.75
- Resistance Level
- SANA $5.33
- COLL $31.51
- Average True Range (ATR)
- SANA 0.35
- COLL 0.92
- MACD
- SANA -0.14
- COLL -0.30
- Stochastic Oscillator
- SANA 3.40
- COLL 23.44
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.